Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells

References

• Dimitriadis G, Mitrou P, Lambadiari V, Maratou E, Raptis SA. Insulin effects in muscle and adipose tissue. Diabetes Res Clin Pract. 2011;93(Suppl 1):S5259. doi:10.1016/S0168-8227(11)70014-6
   Web of Science ®Google Scholar
• Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50(7):1365‐1374. doi:10.1007/s00125-007-0681-5
   PubMed Web of Science ®Google Scholar
• Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007;121(4):856‐862. doi:10.1002/ijc.22717
   Web of Science ®Google Scholar
• Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300(23):2754‐2764. doi:10.1001/jama.2008.824
   PubMed Web of Science ®Google Scholar
• Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer. 2011;47(13):1928‐1937. doi:10.1016/j.ejca.2011.03.003
   Web of Science ®Google Scholar
• Jiang Y, Ben Q, Shen H, Lu W, Zhang Y, Zhu J. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2011;26(11):863‐876. doi:10.1007/s10654-011-9617-y
   PubMed Web of Science ®Google Scholar
• Wang C, Wang X, Gong G, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130(7):1639‐1648. doi:10.1002/ijc.26165
   Web of Science ®Google Scholar
• Renehan AG, Yeh HC, Johnson JA, et al. Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia. 2012;55(6):1619‐1632. doi:10.1007/s00125-012-2526-0
   Web of Science ®Google Scholar
• Tsujimoto T, Kajio H, Sugiyama T. Association between hyperinsulinemia and increased risk of cancer death in nonobese and obese people: A population-based observational study. Int J Cancer. 2017;141(1):102‐111. doi:10.1002/ijc.30729
   PubMed Web of Science ®Google Scholar
• Bruning PF, Bonfrèr JM, van Noord PA, Hart AA, de Jong-bakker M, Nooijen WJ. Insulin resistance and breast-cancer risk. Int J Cancer. 1992;52(4):511‐516. doi:10.1002/ijc.2910520402
   PubMed Web of Science ®Google Scholar
• Djiogue S, Nwabo Kamdje AH, Vecchio L, et al. Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer. 2013;20(1):R1R17. doi:10.1530/ERC-12-032423207292
   PubMed Web of Science ®Google Scholar
• Arcidiacono B, Iiritano S, Nocera A, et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res. 2012;2012:789174. doi:10.1155/2012/78917422701472
   PubMed Web of Science ®Google Scholar
• Argirion I, Weinstein SJ, Männistö S, Albanes D, Mondul AM. Serum insulin, glucose, indices of insulin resistance, and risk of lung cancer. Cancer Epidemiol Biomarkers Prev. 2017;26(10):1519‐1524. doi:10.1158/1055-9965.EPI-17-0293
   PubMed Web of Science ®Google Scholar
• Nimptsch K, Kenfield S, Jensen MK, et al. Dietary glycemic index, glycemic load, insulin index, fiber and whole-grain intake in relation to risk of prostate cancer. Cancer Causes Control. 2011;22(1):51‐61. doi:10.1007/s10552-010-9671-x
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Noguchi Y, Doi C, Makino T, Nomura K. Insulin resistance in patients with cancer: relationships with tumor site, tumor stage, body-weight loss, acute-phase response, and energy expenditure. Nutrition. 2001;17(78):590‐593. doi:10.1016/s0899-9007(01)00561-5
   Web of Science ®Google Scholar
• Mu N, Zhu Y, Wang Y, Zhang H, Xue F. Insulin resistance: a significant risk factor of endometrial cancer. Gynecol Oncol. 2012;125(3):751‐757. doi:10.1016/j.ygyno.2012.03.032
   PubMed Web of Science ®Google Scholar
• Li Y, Bian X, Wei S, He M, Yang Y. The relationship between pancreatic cancer and type 2 diabetes: cause and consequence. Cancer Manag Res. 2019;11:8257‐8268. doi:10.2147/CMAR.S211972
   Web of Science ®Google Scholar
• Antoniadis AG, Petridou ET, Antonopoulos CN, et al. Insulin resistance in relation to melanoma risk. Melanoma Res. 2011;21(6):541‐546. doi:10.1097/CMR.0b013e32834b0eeb
   PubMed Web of Science ®Google Scholar
• Sevim DG, Kiratli H. Serum adiponectin, insulin resistance, and uveal melanoma: clinicopathological correlations. Melanoma Res. 2016;26(2):164‐172. doi:10.1097/CMR.0000000000000226
   PubMed Web of Science ®Google Scholar
• Scoppola A, Strigari L, Barnabei A, et al. Insulin resistance as a risk factor for cutaneous melanoma. A case control study and risk-assessment nomograms. Front Endocrinol. 2019;10:757. doi:10.3389/fendo.2019.00757
   PubMed Web of Science ®Google Scholar
• Wilcox G. Insulin and insulin resistance. Clin Biochem Rev. 2005;26(2):19‐39.
   PubMedGoogle Scholar
• Wagner EF, Petruzzelli M. Cancer metabolism: A waste of insulin interference. Nature. 2015;521(7553):430‐431. doi:10.1038/521430a
   PubMed Web of Science ®Google Scholar
• Honors MA, Kinzig KP. The role of insulin resistance in the development of muscle wasting during cancer cachexia. J Cachexia Sarcopenia Muscle. 2012;3(1):5‐11. doi:10.1007/s13539-011-0051-5
   PubMed Web of Science ®Google Scholar
• Dev R, Bruera E, Dalal S. Insulin resistance and body composition in cancer patients. Ann Oncol. 2018;29(Suppl 2):ii18ii26. doi:10.1093/annonc/mdx815
   Web of Science ®Google Scholar
• Peacock JL, Norton JA. Impact of insulin on survival of cachectic tumor-bearing rats. JPEN J Parenter Enteral Nutr. 1988;12(3):260‐264. doi:10.1177/0148607188012003260
   PubMed Web of Science ®Google Scholar
• Beck SA, Tisdale MJ. Effect of insulin on weight loss and tumour growth in a cachexia model. Br J Cancer. 1989;59(5):677‐681. doi:10.1038/bjc.1989.140
   PubMed Web of Science ®Google Scholar
• Lundholm K, Körner U, Gunnebo L, et al. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin Cancer Res. 2007;13(9):2699‐2706. doi:10.1158/1078-0432.CCR-06-2720
   Web of Science ®Google Scholar
• Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res. 2008;14(20):6364‐6370. doi:10.1158/1078-0432.CCR-07-4879
   PubMed Web of Science ®Google Scholar
• Malaguarnera R, Belfiore A. The insulin receptor: a new target for cancer therapy. Front Endocrinol. 2011;2:93. doi:10.3389/fendo.2011.00093
   PubMedGoogle Scholar
• Poloz Y, Stambolic V. Obesity and cancer, a case for insulin signaling. Cell Death Dis. 2015;6(12):e2037. doi:10.1038/cddis.2015.38126720346
   PubMedGoogle Scholar
• De Luca A, Maiello MR, D’Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012;16(Suppl 2):S17S27. doi:10.1517/14728222.2011.639361
   Web of Science ®Google Scholar
• Asati V, Mahapatra DK, Bharti SK. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives. Eur J Med Chem. 2016;109:314‐341. doi:10.1016/j.ejmech.2016.01.012
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681‐1696. doi:10.1016/j.cell.2015.05.044.
   Web of Science ®Google Scholar
• National Cancer Institute. Drugs Approved for Melanoma. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/melanoma. Accessed 424, 2020.
   Google Scholar
• Suleymanova N, Crudden C, Worrall C, Dricu A, Girnita A, Girnita L. Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation. Oncotarget. 2017;8(47):8225682267. doi:10.18632/oncotarget.19286
   Google Scholar
• Reuveni H, Flashner-Abramson E, Steiner L, et al. Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res. 2013;73(14):43834394. doi:10.1158/0008-5472.CAN-12-3385
   Web of Science ®Google Scholar
• Deuker MM, Marsh Durban V, Phillips WA, McMahon M. PI3ʹ-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer Discov. 2015;5(2):143153. doi:10.1158/2159-8290.CD-14-0856
   Web of Science ®Google Scholar
• Hartman ML, Sztiller-Sikorska M, Gajos-Michniewicz A, Czyz M. Dissecting mechanisms of melanoma resistance to BRAF and MEK inhibitors revealed genetic and non-genetic patient- and drug-specific alterations and remarkable phenotypic plasticity. Cells. 2020;9(1):142. doi:10.3390/cells9010142
   PubMed Web of Science ®Google Scholar
• Hartman ML, Talar B, Sztiller-Sikorska M, Nejc D, Czyz M. Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations. Oncotarget. 2016;7(8):9026‐9040. doi:10.18632/oncotarget.7030
   Google Scholar
• Hartman ML, Sztiller-Sikorska M, Czyz M. Whole-exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cells. Mol Carcinog. 2019;58(4):588‐602. doi:10.1002/mc.22953
   PubMed Web of Science ®Google Scholar
• Hartman ML, Rozanski M, Osrodek M, Zalesna I, Czyz M. Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells. Lab Invest. 2017;97(2):217‐227. doi:10.1038/labinvest.2016.140
   PubMed Web of Science ®Google Scholar
• Zalesna I, Osrodek M, Hartman ML, et al. Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro. PLoS One. 2017;12(8):e0183498. doi:10.1371/journal.pone.018349828829835
   PubMed Web of Science ®Google Scholar
• Osrodek M, Hartman ML, Czyz M. Physiologically relevant oxygen concentration (6% O2) as an important component of the microenvironment impacting melanoma phenotype and melanoma response to targeted therapeutics in vitro. Int J Mol Sci. 2019;20(17):4203. doi:10.3390/ijms20174203
   PubMed Web of Science ®Google Scholar
• Hartman ML, Czyz M. TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAFV600E melanoma cells. Arch Dermatol Res. 2019. doi:10.1007/s00403-019-01995-w
   PubMed Web of Science ®Google Scholar
• Czyz M, Sztiller-Sikorska M, Gajos-Michniewicz A, Osrodek M, Hartman ML. Plasticity of drug-naïve and vemurafenib- or trametinib-resistant melanoma cells in execution of differentiation/pigmentation program. J Oncol. 2019;2019:1697913. doi:10.1155/2019/169791331354817
   PubMed Web of Science ®Google Scholar
• The cBioPortal for cancer genomics. Available from: https://www.cbioportal.org. Accessed 125, 2020.
   Google Scholar
• Keyoto Encyclopedia of Genes and Genomes (KEGG). Available from https://www.kegg.jp. Accessed 125, 2020.
   Google Scholar
• Sztiller-Sikorska M, Koprowska K, Jakubowska J, et al. Sphere formation and self-renewal capacity of melanoma cells is affected by the microenvironment. Melanoma Res. 2012;22(3):215‐224. doi:10.1097/CMR.0b013e3283531317
   PubMed Web of Science ®Google Scholar
• Boiko AD, Razorenova OV, van de Rijn M, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 2010;466(7302):133‐137. doi:10.1038/nature09161
   PubMed Web of Science ®Google Scholar
• Redmer T, Welte Y, Behrens D, et al. The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells. PLoS One. 2014;9(5):e92596. doi:10.1371/journal.pone.009259624799129
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7‐30. doi:10.3322/caac.21590
   Web of Science ®Google Scholar
• Crocetti E, Mallone S, Robsahm TE, et al. Survival of patients with skin melanoma in Europe increases further: results of the EUROCARE-5 study. Eur J Cancer. 2015;51(15):2179‐2190. doi:10.1016/j.ejca.2015.07.039
   PubMed Web of Science ®Google Scholar
• Iadeluca L, Mardekian J, Chander P, Hopps M, Makinson GT. The burden of selected cancers in the US: health behaviors and health care resource utilization. Cancer Manag Res. 2017;9:721‐730. doi:10.2147/CMAR.S143148
   PubMed Web of Science ®Google Scholar
• Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - update 2019. Eur J Cancer. 2020;126:159‐177. doi:10.1016/j.ejca.2019.11.015
   Web of Science ®Google Scholar
• Kozar I, Margue C, Rothengatter S, Haan C, Kreis S. Many ways to resistance: how melanoma cells evade targeted therapies. Biochim Biophys Acta Rev Cancer. 2019;1871(2):313‐322. doi:10.1016/j.bbcan.2019.02.002
   PubMed Web of Science ®Google Scholar
• Tian Y, Guo W. A review of the molecular pathways involved in resistance to braf inhibitors in patients with advanced-stage melanoma. Med Sci Monit. 2020;26:e920957. doi:10.12659/MSM.92095732273491
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30‐39. doi:10.1056/NEJMoa1412690
   Web of Science ®Google Scholar
• Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500‐504. doi:10.1038/nature11183
   PubMed Web of Science ®Google Scholar
• Filitis DC, Rauh J, Mahalingam M. The HGF-cMET signaling pathway in conferring stromal-induced BRAF-inhibitor resistance in melanoma. Melanoma Res. 2015;25(6):470‐478. doi:10.1097/CMR.0000000000000194
   PubMed Web of Science ®Google Scholar
• Rohrbeck L, Gong JN, Lee EF, et al. Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM. Cell Death Differ. 2016;23(12):2054‐2062. doi:10.1038/cdd.2016.96
   PubMed Web of Science ®Google Scholar
• Grimm J, Hufnagel A, Wobser M, et al. BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1. Oncogenesis. 2018;7(9):71. doi:10.1038/s41389-018-0082-230237393
   PubMedGoogle Scholar
• Czyz M. HGF/c-MET signaling in melanocytes and melanoma. Int J Mol Sci. 2018;19(12):3844. doi:10.3390/ijms19123844
   PubMed Web of Science ®Google Scholar
• Czyz M. Fibroblast growth factor receptor signaling in skin cancers. Cells. 2019;8(6):540. doi:10.3390/cells8060540
   PubMed Web of Science ®Google Scholar
• Chi M, Ye Y, Zhang XD, Chen J. Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway. Drug Des Devel Ther. 2014;8:255‐262. doi:10.2147/DDDT.S53568
   PubMed Web of Science ®Google Scholar
• Roesch A. Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma. Oncogene. 2015;34(23):2951‐2957. doi:10.1038/onc.2014.249
   PubMed Web of Science ®Google Scholar
• Tomellini E, Touil Y, Lagadec C, et al. Nerve growth factor and proNGF simultaneously promote symmetric self-renewal, quiescence, and epithelial to mesenchymal transition to enlarge the breast cancer stem cell compartment. Stem Cells. 2015;33(2):342‐353. doi:10.1002/stem.1849
   PubMed Web of Science ®Google Scholar
• Civenni G, Walter A, Kobert N, et al. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res. 2011;71(8):3098‐3109. doi:10.1158/0008-5472.CAN-10-3997
   PubMed Web of Science ®Google Scholar
• Li S, Yue D, Chen X, et al. Epigenetic regulation of CD271, a potential cancer stem cell marker associated with chemoresistance and metastatic capacity. Oncol Rep. 2015;33(1):425‐432. doi:10.3892/or.2014.3569
   Web of Science ®Google Scholar
• Lehraiki A, Cerezo M, Rouaud F, et al. Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib. Cell Discov. 2015;1:15030. doi:10.1038/celldisc.2015.3027462428
   PubMed Web of Science ®Google Scholar
• Redmer T, Walz I, Klinger B, et al. The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells. Oncogenesis. 2017;6(1):e291. doi:10.1038/oncsis.2016.8828112719
   PubMedGoogle Scholar
• Warters RL, Adamson PJ, Pond CD, Leachman SA. Melanoma cells express elevated levels of phosphorylated histone H2AX foci. J Invest Dermatol. 2005;124(4):807–817. doi:10.1111/j.0022-202X.2005.23674.x15816840
   PubMed Web of Science ®Google Scholar
• McManus KJ, Hendzel MJ. ATM-dependent DNA damage-independent mitotic phosphorylation of H2AX in normally growing mammalian cells. Mol Biol Cell. 2005;16(10):5013–5025. doi:10.1091/mbc.e05-01-006516030261
   PubMed Web of Science ®Google Scholar
• An J, Huang YC, Xu QZ, et al. DNA-PKcs plays a dominant role in the regulation of H2AX phosphorylation in response to DNA damage and cell cycle progression. BMC Mol Biol. 2010;11:18. doi:10.1186/1471-2199-11-1820205745
   PubMed Web of Science ®Google Scholar
• Robb R, Yang L, Shen C, et al. Inhibiting BRAF oncogene-mediated radioresistance effectively radiosensitizes BRAFV600E-mutant thyroid cancer cells by constraining DNA double-strand break repair. Clin Cancer Res. 2019;25(15):4749–4760. doi:10.1158/1078-0432.CCR-18-362531097454
   PubMed Web of Science ®Google Scholar
• Gopal YN, Deng W, Woodman SE, et al. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res. 2010;70(21):8736–8747. doi:10.1158/0008-5472.CAN-10-090220959481
   PubMed Web of Science ®Google Scholar
• Deng W, Gopal YN, Scott A, Chen G, Woodman SE, Davies MA. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res. 2012;25(2):248–258. doi:10.1111/j.1755-148X.2011.00950.x22171948
   PubMed Web of Science ®Google Scholar
• Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18(6):683–695. doi:10.1016/j.ccr.2010.11.02321156289
   PubMed Web of Science ®Google Scholar
• Herkert B, Kauffmann A, Mollé S, et al. Maximizing the efficacy of MAPK-targeted treatment in PTENLOF/BRAFMUT melanoma through PI3K and IGF1R Inhibition. Cancer Res. 2016;76(2):390–402. doi:10.1158/0008-5472.CAN-14-335826577700
   PubMed Web of Science ®Google Scholar
• Benito-Jardón L, Díaz-Martínez M, Arellano-Sánchez N, Vaquero-Morales P, Esparís-Ogando A, Teixidó J. Resistance to MAPK inhibitors in melanoma involves activation of the IGF1R-MEK5-Erk5 Pathway. Cancer Res. 2019;79(9):2244–2256. doi:10.1158/0008-5472.CAN-18-276230833419
   PubMed Web of Science ®Google Scholar
• Al-Alwan MM, Okkenhaug K, Vanhaesebroeck B, Hayflick JS, Marshall AJ. Requirement for phosphoinositide 3-kinase p110delta signaling in B cell antigen receptor-mediated antigen presentation. J Immunol. 2007;178(4):2328‐2335. doi:10.4049/jimmunol.178.4.2328
   Web of Science ®Google Scholar
• Zebedin E, Simma O, Schuster C, et al. Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood. 2008;112(12):4655‐4664. doi:10.1182/blood-2008-02-139105
   PubMed Web of Science ®Google Scholar
• Dornan GL, Siempelkamp BD, Jenkins ML, Vadas O, Lucas CL, Burke JE. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in PIK3CD and PIK3R1. Proc Natl Acad Sci U S A. 2017;114(8):1982‐1987. doi:10.1073/pnas.1617244114
   PubMed Web of Science ®Google Scholar
• Sawyer C, Sturge J, Bennett DC, et al. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res. 2003;63(7):1667‐1675.
   PubMed Web of Science ®Google Scholar
• Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251–263. doi:10.1016/j.cell.2012.06.02422817889
   PubMed Web of Science ®Google Scholar
• Hayward NK, Wilmott JS, Waddell N, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545(7653):175–180. doi:10.1038/nature2207128467829
   PubMed Web of Science ®Google Scholar
• Kwong LN, Davies MA. Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. Clin Cancer Res. 2013;19(19):5310–5319. doi:10.1158/1078-0432.CCR-13-014224089444
   PubMed Web of Science ®Google Scholar
• Dong L, Jin L, Tseng HY, et al. Oncogenic suppression of PHLPP1 in human melanoma. Oncogene. 2014;33(39):4756–4766. doi:10.1038/onc.2013.42024121273
   PubMed Web of Science ®Google Scholar
• Ye Y, Jin L, Wilmott JS, et al. PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nat Commun. 2013;4:1508. doi:10.1038/ncomms248923443536
   PubMed Web of Science ®Google Scholar
• Baserga R. The decline and fall of the IGF-I receptor. J Cell Physiol. 2013;228(4):675–679. doi:10.1002/jcp.2421722926508
   PubMed Web of Science ®Google Scholar
• Janssen JA, Varewijck AJ. IGF-IR targeted therapy: past, present and future. Front Endocrinol. 2014;5:224. doi:10.3389/fendo.2014.00224
   PubMed Web of Science ®Google Scholar
• Osher E, Macaulay VM. Therapeutic targeting of the IGF axis. Cells. 2019;8(8):895. doi:10.3390/cells8080895
   PubMed Web of Science ®Google Scholar
• Garofalo C, Manara MC, Nicoletti G, et al. Efficacy of and resistance to anti-IGF-1R therapies in Ewing’s sarcoma is dependent on insulin receptor signaling. Oncogene. 2011;30(24):2730–2740. doi:10.1038/onc.2010.64021278796
   PubMed Web of Science ®Google Scholar
• Koundouros N, Poulogiannis G. Phosphoinositide 3-Kinase/Akt signaling and redox metabolism in cancer. Front Oncol. 2018;8:160. doi:10.3389/fonc.2018.0016029868481
   PubMed Web of Science ®Google Scholar
• Wang L, Chen Y, Sternberg P, Cai J. Essential roles of the PI3 kinase/Akt pathway in regulating Nrf2-dependent antioxidant functions in the RPE. Invest Ophthalmol Vis Sci. 2008;49(4):1671‐1678. doi:10.1167/iovs.07-1099
   Web of Science ®Google Scholar
• Chen HH, Chen YT, Huang YW, Tsai HJ, Kuo CC. 4-Ketopinoresinol, a novel naturally occurring ARE activator, induces the Nrf2/HO-1 axis and protects against oxidative stress-induced cell injury via activation of PI3K/AKT signaling. Free Radic Biol Med. 2012;52(6):1054‐1066. doi:10.1016/j.freeradbiomed.2011.12.012
   Web of Science ®Google Scholar
• Li L, Dong H, Song E, Xu X, Liu L, Song Y. Nrf2/ARE pathway activation, HO-1 and NQO1 induction by polychlorinated biphenyl quinone is associated with reactive oxygen species and PI3K/AKT signaling. Chem Biol Interact. 2014;209:56‐67. doi:10.1016/j.cbi.2013.12.005
   PubMed Web of Science ®Google Scholar
• Khamari R, Trinh A, Gabert PE, et al. Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors. Cell Death Dis. 2018;9(3):325. doi:10.1038/s41419-018-0340-429487283
   PubMedGoogle Scholar
• Wang L, Leite de Oliveira R, Huijberts S, et al. An acquired vulnerability of drug-resistant melanoma with therapeutic potential. Cell. 2018;173(6):1413‐1425.e14. doi:10.1016/j.cell.2018.04.012
   Web of Science ®Google Scholar
• Yuan L, Mishra R, Patel H, et al. Utilization of reactive oxygen species targeted therapy to prolong the efficacy of BRAF inhibitors in melanoma. J Cancer. 2018;9(24):4665‐4676. doi:10.7150/jca.27295
   Web of Science ®Google Scholar
• Gopal YN, Rizos H, Chen G, et al. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma. Cancer Res. 2014;74(23):7037‐7047. doi:10.1158/0008-5472.CAN-14-1392
   Web of Science ®Google Scholar
• Iqbal MA, Siddiqui FA, Gupta V, et al. Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2. Mol Cancer. 2013;12:72. doi:10.1186/1476-4598-12-7223837608
   PubMed Web of Science ®Google Scholar
• Wagle A, Jivraj S, Garlock GL, Stapleton SR. Insulin regulation of glucose-6-phosphate dehydrogenase gene expression is rapamycin-sensitive and requires phosphatidylinositol 3-kinase. J Biol Chem. 1998;273(24):14968‐14974. doi:10.1074/jbc.273.24.14968
   PubMed Web of Science ®Google Scholar
• Jin L, Zhou Y. Crucial role of the pentose phosphate pathway in malignant tumors. Oncol Lett. 2019;17(5):4213‐4221. doi:10.3892/ol.2019.10112
   Web of Science ®Google Scholar
• Lo M, Wang YZ, Gout PW. The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol. 2008;215(3):593‐602. doi:10.1002/jcp.21366
   PubMed Web of Science ®Google Scholar
• Yang Y, Yee D. IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC-. Cancer Res. 2014;74(8):2295‐2305. doi:10.1158/0008-5472.CAN-13-1803
   Web of Science ®Google Scholar
• Lim JKM, Delaidelli A, Minaker SW, et al. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Proc Natl Acad Sci U S A. 2019;116(19):9433‐9442. doi:10.1073/pnas.1821323116
   Web of Science ®Google Scholar
• Traverso N, Ricciarelli R, Nitti M, et al. Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev. 2013;2013:972913. doi:10.1155/2013/97291323766865
   PubMed Web of Science ®Google Scholar
• Ghoshal N, Sharma S, Banerjee A, Kurkalang S, Raghavan SC, Chatterjee A. Influence of reduced glutathione on end-joining of DNA double-strand breaks: cytogenetical and molecular approach. Mutat Res. 2017;795:1‐9. doi:10.1016/j.mrfmmm.2016.10.005
   PubMed Web of Science ®Google Scholar
• Estrela JM, Ortega A, Obrador E. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci. 2006;43(2):143–181. doi:10.1080/1040836050052387816517421
   PubMed Web of Science ®Google Scholar
• Maertens O, Kuzmickas R, Manchester HE, et al. MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability in BRAF-, NRAS-, and NF1-mutant melanomas. Cancer Discov. 2019;9(4):526‐545. doi:10.1158/2159-8290.CD-18-0879
   PubMed Web of Science ®Google Scholar
• Hopkins BD, Pauli C, Du X, et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018;560(7719):499‐503. doi:10.1038/s41586-018-0343-4
   PubMed Web of Science ®Google Scholar
• Lv M, Zhu X, Wang H, Wang F, Guan W. Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: a systematic review and meta-analysis. PLoS One. 2014;9(12):e115147. doi:10.1371/journal.pone.011514725502434
   PubMed Web of Science ®Google Scholar
• Allen BG, Bhatia SK, Anderson CM, et al. Ketogenic diets as an adjuvant cancer therapy: history and potential mechanism. Redox Biol. 2014;2:963‐970. doi:10.1016/j.redox.2014.08.002
   PubMed Web of Science ®Google Scholar
• Paddock MN, Field SJ, Cantley LC. Treating cancer with phosphatidylinositol-3-kinase inhibitors: increasing efficacy and overcoming resistance. J Lipid Res. 2019;60(4):747‐752. doi:10.1194/jlr.S092130
   PubMed Web of Science ®Google Scholar